MarketFriction

Fermenta Biotech Ltd

NSE FERMENTA · BSE 506414 · Pharmaceuticals
₹553.25 +0.65%
NSE close2026-10-01
52 week range248.85 - 580.45
Market cap₹1,629 Cr.
P/E29.8
Price band 20% Delivery 24.0%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales56.9198.9797.3478.1395.03156.47139.85136.26130.22137.36121.58121.82
Expenses70.8273.8491.9677.3376.25103.20102.90108.02103.58112.40101.58103.76
Operating Profit-13.9125.135.380.8018.7853.2736.9528.2426.6424.9620.0018.06
OPM %-24.44%25.39%5.53%1.02%19.76%34.04%26.42%20.73%20.46%18.17%16.45%14.83%
Other Income-5.532.525.382.822.882.233.898.775.430.9214.144.37
Interest3.695.193.393.433.694.082.993.112.583.032.822.54
Depreciation5.936.386.466.126.156.085.865.815.415.375.115.20
Profit before tax-29.0616.080.91-5.9311.8245.3431.9928.0924.0817.4826.2114.69
Tax %0.00%37.81%884.62%0.00%5.92%16.43%-4.19%23.07%25.17%31.24%29.03%35.13%
Net Profit-29.079.99-7.14-5.9311.1237.8933.3221.6018.0312.0218.609.53
EPS in Rs-9.703.35-2.36-1.983.8712.5411.687.426.144.316.523.31
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales155164302403292376397349335468523511
Expenses134152209248225293335330307352422421
Operating Profit211293156668362182811510190
OPM %13%7%31%39%23%22%16%5%8%25%19%18%
Other Income13961288-20472925
Interest61014212019182117151311
Depreciation81012121520262825242221
Profit before tax7-676129435227-51-10839682
Tax %61%49%28%8%-37%18%44%4%143%8%27%
Net Profit2-946117604315-53-24767058
EPS in Rs-0.41-4.1412.2142.7120.2315.465.25-17.36-7.8426.1224.3920.28
Dividend Payout %-51%-5%2%1%24%16%23%-7%-16%9%15%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth13%7%14%-3%
Compounded Profit Growth51%7%65%-48%
Stock Price CAGR23%15%52%72%
Return on Equity13%7%13%16%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital2222514141414141514
Reserves129128142122246295346358301274348392
Borrowings718987173209224232239220139115113
Other Liabilities6070758792809496102120137128
Total Liabilities262288307385551614687707637548614648
Fixed Assets85168172177178200263299267269227220
CWIP65654227157354521613
Investments1815181080003000
Other Assets9499112193344342367373321277372414
Total Assets262288307385551614687707637548614648
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity154259903463431161054193
Cash from Investing Activity-18-137-101-97-44-41-26-55-16-0-43
Cash from Financing Activity110-128912-47-1-22-41-91-51-42
Net Cash Flow-21-4476-5721-419-1-108
Free Cash Flow-20-25-174255-347676863863
CFO/OP119%35%35%83%79%73%92%85%610%370%38%108%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9110199835987668044767478
Inventory Days125160208234347594441380309245285290
Days Payable95113147183169260169154109182178147
Cash Conversion Cycle122148160134237421338306244139181221
Working Capital Days-61-49335443705467-1894096
ROCE %3%6%2%31%41%12%13%7%-0%3%23%21%
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Aug 2026
Promoters62.06%62.06%62.06%62.06%62.06%64.08%64.08%64.08%64.08%64.08%64.08%64.09%
FIIs0.00%0.00%0.00%0.05%0.02%0.02%0.02%0.02%0.02%0.02%0.13%0.37%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.04%0.04%
Public36.05%36.05%36.11%36.41%36.98%35.00%35.00%34.75%33.99%33.32%33.19%32.95%
Others1.89%1.89%1.82%1.47%0.94%0.89%0.89%1.14%1.90%2.58%2.55%2.55%
No. of Shareholders15,15015,17814,58913,22112,92212,93012,84513,76014,13913,66114,13114,777

Fundamentals

Market Cap₹ 1,629 Cr.
Current Price₹ 551
Stock P/E29.8
Book Value₹ 138
ROCE20.6 %
ROE16.4 %
Dividend Yield0.68 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)-3%
Compounded Profit Growth (TTM)-48%
Consolidated figures.
Valuation
Market capRs 1,628 Cr
Enterprise valueRs 1,700 Cr
P/E (TTM)27.29x
Price to book4.01x
Price to sales3.19x
EV / EBITDA14.85x
EV / EBIT18.20x
EV / sales3.33x
Price to cash flow17.54x
Earnings yield3.66%
Dividend yield0.66%
P/E, 3-year average11.78x
P/B, 3-year average2.02x
P/E, 5-year average20.91x
P/B, 5-year average1.74x
Profitability
Operating margin (excl. other income)19.30%
Operating margin (incl. other income)24.89%
EBITDA margin22.41%
Pre-tax margin16.14%
Net profit margin11.68%
Net margin, latest quarter8.00%
ROE18.67%
ROCE21.77%
ROA11.37%
ROE, 3-year average11.54%
ROCE, 3-year average15.00%
ROA, 3-year average6.90%
ROE, 5-year average4.80%
ROCE, 5-year average9.45%
ROA, 5-year average3.06%
ROIC (approx.)14.32%
Tax rate26.72%
Other income / net worth7.20%
Growth
Sales growth (latest year)11.91%
Profit growth (latest year)-6.62%
Sales CAGR, 3 years14.47%
Sales CAGR, 5 years6.85%
Profit CAGR, 5 years9.54%
Sales growth QoQ0.20%
Profit growth QoQ-49.24%
Sales growth YoY (latest quarter)-10.60%
Profit growth YoY (latest quarter)-55.38%
Per share
EPS (TTM)Rs 20.27
EPS (latest year)Rs 24.39
EPS (latest quarter)Rs 3.31
EPS, 3-year averageRs 14.22
EPS, 5-year averageRs 6.11
Book value per shareRs 138.02
Sales per shareRs 173.62
Cash flow per shareRs 31.54
Free cash flow per shareRs 21.41
Dividend per share (latest year)Rs 3.66
Dividend per share, 3-year averageRs 2.45
Dividend per share, 5-year averageRs 1.96
Dividends
Dividend payout14.99%
Dividend payout, 3-year average12.24%
Dividend payout, 5-year average15.93%
Efficiency
Asset turnover0.81x
Fixed asset turnover2.38x
Inventory turnover1.77x
Inventory days207 days
Debtor days78 days
Debtors turnover4.69x
Creditor days147 days
Cash conversion cycle221 days
Working capital days96 days
Leverage
Total debtRs 113 Cr
Cash and bankRs 41 Cr
Net debtRs 72 Cr
Debt to equity0.28x
Net debt / EBITDA0.63x
Interest coverage8.52x
Owners' fund to total sources62.70%
Debt to assets17.49%
Cash flow
Cash from Operating Activity (latest year)Rs 93 Cr
Cash from Investing Activity (latest year)Rs -43 Cr
Cash from Financing Activity (latest year)Rs -42 Cr
Net Cash Flow (latest year)Rs 8 Cr
Free cash flow (latest year)Rs 63 Cr
FCFE (approx.: FCF + change in debt)Rs 61 Cr
Cash from ops / profit, 5 years4.74x
Sales to cash flow5.64x
Statement figures
Net sales (TTM)Rs 511 Cr
Net sales (latest year)Rs 523 Cr
Sales (latest quarter)Rs 122 Cr
Operating profit excl. other income (latest year)Rs 101 Cr
Operating profit (latest quarter)Rs 18 Cr
Other income (TTM)Rs 25 Cr
EBITDA (TTM)Rs 115 Cr
PBDT (TTM)Rs 104 Cr
Profit before tax (TTM)Rs 82 Cr
Tax (latest year)Rs 26 Cr
Net profit (TTM)Rs 60 Cr
Net profit (latest year)Rs 72 Cr
Net profit (latest quarter)Rs 10 Cr
Depreciation (TTM)Rs 21 Cr
Depreciation (latest quarter)Rs 5 Cr
Interest (TTM)Rs 11 Cr
Cost of goods sold (latest year)Rs 270 Cr
Total expenditure (latest year)Rs 422 Cr
Total income (latest year)Rs 552 Cr
Share capitalRs 14 Cr
ReservesRs 392 Cr
Shareholders' fundsRs 406 Cr
Total assetsRs 648 Cr
Net blockRs 220 Cr
Capital work in progressRs 13 Cr
InvestmentsRs 0 Cr
ReceivablesRs 112 Cr
InventoryRs 153 Cr
Other liabilitiesRs 128 Cr
Shares outstanding (crore)2.94
Ownership
Promoter holding64.09% (+0.01 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 27.3 is at the 84th percentile of its own 6.8-year range (median 17.8, low 4.8, high 39.5).
P/B 4.01 is at the 84th percentile (median 2.63).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodFERMENTANifty 50Difference
1 week+15.7%-2.8% +18.5 pts
1 month+13.9%-6.8% +20.7 pts
3 months+61.3%-7.6% +68.9 pts
3 years+250.3%+14.2% +236.1 pts
5 years+106.1%+27.9% +78.2 pts
1 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 1 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.03%0 -14%

Red flags

F-score 6 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹122 Cr -10.6% vs Jun 2025. Net profit ₹10 Cr -55.9%.
Against our estimate for Jun 2026: sales +2.3%, profit -45.1% in line. Our estimate for Sep 2026: sales Rs 115 Cr, profit Rs 13 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
DateClientSideQtyPrice
2026-09-29Qe Securities LlpSELL147,373547.11
2026-09-29Qe Securities LlpBUY143,855551.69
2026-09-29Alphagrep Securities Private LimitedSELL166,836547.97
2026-09-29Alphagrep Securities Private LimitedBUY166,836547.61
2026-09-28Thakkar PreetiSELL1,165,938474.65
2026-09-28Molecule Ventures Limited Liability PartnershipBUY257,000475.25
2026-09-28Anant JainBUY231,611473.92
Ex-dateActionFactor
2026-08-05Dividend - Rs 3.75 Per Share
DateTypeWhat it says
2026-10-01Concall / analyst meetSchedule of investor(s) meeting to be held on October 07, 2026.
2026-09-29Concall / analyst meetSchedule of investor(s) meeting to be held on October 05, 2026.
2026-09-24Concall / analyst meetSchedule of investor(s) meet
2026-09-21Concall / analyst meetSchedule of investor(s) meeting.
2026-09-17Concall / analyst meetSchedule of investor(s) meet
2026-09-16General UpdatesDispatch of letters to shareholders regarding transfer of Equity Shares of the Company to the Investor Education and Protection Fund ( IEPF ) Account.
2026-09-08UpdatesPress Release regarding exclusive Licence Agreement with Vellore Institute of Technology ( VIT ), Vellore for Vitamin B12 Fortification Technology.
2026-09-04UpdatesResubmission of the outcome filed on August 11, 2026, in machine readable format, in response to the e-mail received dated September 03, 2026.
2026-08-27Concall / analyst meetSchedule of investor(s) meeting(s) to held on September 03 2026.
2026-08-17Concall / analyst meetSchedule of investor(s) meeting to be held on August 21, 2026.
2026-08-17Credit Rating- RevisionRevision in Credit Rating.
2026-08-11General UpdatesDeclaration of Voting Results of the 74th Annual General Meeting.
2026-08-11Shareholder meetingVoting results.
2026-08-11Shareholder meetingProceedings of Annual General Meeting held on August 11, 2026
2026-08-11General UpdatesPresentation to be made for shareholders at 74th Annual General Meeting of the Company.
2026-08-11Investor PresentationInvestor Presentation
2026-08-11Press ReleaseA press release dated August 11, 2026, titled "Press release regarding unaudited financial results of Q1FY27.".
2026-08-11Board meeting outcomeFermenta Biotech Limited has submitted to the Exchange, the unaudited financial results (standalone and consolidated) for the quarter ended Jun 30, 20...
2026-08-10Concall / analyst meetSchedule of meeting.
2026-08-04Press ReleaseA press release dated August 04, 2026, titled "Press release - Listing of shares on NSE.".
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 100perc in previous 6 months

Quick answers

What is the market cap of Fermenta Biotech Ltd?

Fermenta Biotech Ltd (FERMENTA) has a market capitalisation of Rs 1,629 Cr. at the 2026-10-01 close.

What is the P/E ratio of Fermenta Biotech Ltd?

Fermenta Biotech Ltd trades at a P/E of 29.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were Fermenta Biotech Ltd's latest quarterly results?

In the Jun 2026 quarter, Fermenta Biotech Ltd sales was Rs 122 Cr (-10.6% vs Jun 2025) and net profit was Rs 10 Cr.

What is the 52-week high and low of Fermenta Biotech Ltd?

The 52-week high is Rs 580.45 and the 52-week low is Rs 248.85.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03